JMP Group Expands Life Sciences Investment Banking and Equity Research Platforms
JMP Group LLC (NYSE: JMP) announced key appointments at JMP Securities, enhancing its biopharma corporate finance team. Fedora Baloiu joins as managing director and co-head, alongside Silvan Tuerkcan and Gobind Singh as senior equity research analysts. David Kellman will also serve as co-head of biopharma corporate finance, while David Schechner heads mergers and acquisitions. These appointments aim to leverage existing relationships and expand coverage in the biotechnology sector, positioning JMP as a stronger resource in the life sciences industry.
- Key appointments strengthen JMP Securities' biopharma team.
- Enhances existing equity research and investment banking capabilities.
- Leverages established industry relationships of new executives.
- None.
JMP Group LLC (NYSE: JMP), an investment banking and alternative asset management firm, announced today that Fedora Baloiu has joined JMP Securities as a managing director and co-head of biopharma corporate finance. Additionally, Silvan Tuerkcan and Gobind Singh, a director and vice president, respectively, have both joined JMP Securities as senior equity research analysts focused on the biotechnology sector. All three are based in the firm’s New York office.
In connection with these key additions to JMP Securities’ life sciences franchise, David Kellman, a managing director and head of healthcare investment banking, will also serve as co-head of biopharma corporate finance, while David Schechner, a managing director in the healthcare investment banking group, has been named head of biopharma mergers and acquisitions.
“We could not be more enthusiastic about the recent developments in our healthcare group,” said Mark Lehmann, chief executive officer of JMP Securities. “JMP has long been well recognized within the life sciences industry for its equity research and investment banking capabilities, and our platform is now broader than ever before. Our three newest additions will be immediate contributors. Fedora brings longstanding relationships and excellent perspective on the healthcare capital markets, while Silvan and Gobind have already begun to complement our existing biotech research with initial coverage of their own. As a result, we are positioned to build on our success, making our firm an even greater resource for our corporate and institutional clients in the life sciences space.”
Prior to joining JMP Securities, Ms. Baloiu was a managing director and head of U.S. healthcare investment banking at Nomura Securities. She previously served as head of the biopharmaceuticals practice at Houlihan Lokey, after spending nearly a decade in the healthcare investment banking division at Goldman Sachs & Co. Ms. Baloiu began her career as a consultant at Bain & Company in Milan, Italy. She holds a master’s degree in biotechnology from Johns Hopkins University, an MBA from Columbia Business School, and an undergraduate business degree from Italy’s Bocconi University.
Prior to joining JMP Securities, Mr. Tuerkcan was an executive director and senior research analyst covering biotechnology at both UBS and Oppenheimer & Co. He previously worked in equity research at Goldman Sachs & Co. Mr. Tuerkcan began his career as a postdoctoral fellow both at Institut Pasteur & Ecole Polytechnique in France and later at the Stanford University School of Medicine. He holds a PhD in biophysics from France’s Ecole Polytechnique, an MSc in engineering physics from Germany’s TU Munich, and a BSc in physics from Canada’s McGill University.
Prior to joining JMP Securities, Mr. Singh worked in equity research at BMO Capital Markets, with a focus on the biotechnology sector. Before starting his financial services career, Mr. Singh engaged in clinical practice and academic research while a physician at nationally recognized medical centers such as UCSF. He holds MD and PhD degrees from Mount Sinai School of Medicine and an undergraduate degree with concentrations in chemistry, biochemistry, and biology from Boston University.
JMP Securities is a full-service, middle-market investment bank with a healthcare practice consisting of five senior investment bankers, a dedicated senior capital markets professional, and seven equity research analysts covering biotechnology, biopharmaceuticals, and medical devices and supplies. The firm’s healthcare investment banking group executed 51 capital raising and strategic advisory transactions with an aggregate value of
About JMP Group
JMP Group LLC is a diversified capital markets firm that provides investment banking, equity research, and sales and trading services to corporate and institutional clients as well as alternative asset management products and services to institutional and high-net-worth investors. JMP Group conducts its investment banking and research, sales, and trading activities through JMP Securities; its venture capital and private capital activities through Harvest Capital Strategies and JMP Asset Management; and the management of Harvest Capital Credit Corporation (NASDAQ: HCAP), a business development company, through HCAP Advisors. For more information, visit www.jmpg.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005717/en/
FAQ
Who has joined JMP Group's biopharma team?
What roles have Fedora Baloiu and others taken at JMP Group?
How does JMP Group plan to enhance its life sciences offerings?
What is the significance of the new appointments for JMP Group's business?
When were the new appointments announced by JMP Group?
